A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Respiratory Syncytial Virus

In brief

The purpose of this study is to evaluate the efficacy of rilematovir compared to placebo with respect to the time to resolution of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) symptoms.

Key facts

Study ID
NCT04978337
Run by
Janssen Research & Development, LLC
People needed
5
Starts
2021-11-17
Expected to finish
2022-03-31
Last updated by the study team
2024-09-24

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.